DRKS00034478
Completed
未知
Genetic Markers of Response to Newer Therapies for Type 2 Diabetes
Faculty of Medicine, University of Ljubljana0 sites161 target enrollmentJune 14, 2024
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- E11
- Sponsor
- Faculty of Medicine, University of Ljubljana
- Enrollment
- 161
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Criteria 1: previous diagnosis of type 2 diabetes mellitus
- •Criteria 2: met the inclusion criteria for treatment with newer antihyperglycaemic drugs (SGLT2 inhibitors and/or GLP\-1RA inhibitors)
Exclusion Criteria
- •Criteria 1: other types of diabetes mellitus
- •Criteria 2: patients with significant cognitive impairment or psychiatric disorder
- •Criteria 3: patients abusing alcohol or other drugs
- •Criteria 4: patients with cancer or a history of cancer in the last 5 years)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Validation of novel biomarkers for treatment response to rush oral immunotherapy for food allergy in childreFood allergyJPRN-UMIN000029742Department of Clinical Research, Mie National Hospital30
Recruiting
Not Applicable
Predicting the Response of Treatment in CardiomyopathyIdiopathic Dilated CardiomyopathyCardiovascular - Other cardiovascular diseasesACTRN12611000146998Professor Joseph Selvanayagam200
Completed
Not Applicable
Age related macular degeneration pharmacogenetics studyISRCTN44202629eeds Teaching Hospitals NHS Trust (UK)350
Active, not recruiting
Phase 1
Biomarkers of Response to Pembrolizumab Combined with Chemotherapy in Non-Small Cell Lung Cancer (Keynote-782)EUCTR2018-002598-22-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
Active, not recruiting
Phase 1
Biomarkers of Response to Pembrolizumab Combined with Chemotherapy in Non-Small Cell Lung Cancer (Keynote-782)EUCTR2018-002598-22-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100